CD24 and breast carcinoma: In MDA-MB-231 and Hs578T cells, the absence of plasma membrane alterations following benzyl-α-GalNAc treatment indicate probably different O-glycosylation requirements for CD24, or other interacting proteins implicated in the organization of CD24 at the plasma membrane of basal B breast cancer cells.